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Abstract: Mucormycosis is a life threatening infection in patients with haematological disease.
We introduced a Mucorales-PCR and an aggressive, multidisciplinary management approach for
mucormycosis during 2016–2017 and evaluated patient outcomes in 13 patients diagnosed and treated
in 2012–2019. Management principle: repeated surgical debridement until biopsies from the resection
margins were clean as defined by negative Blankophor microscopy, Mucorales-PCR (both reported
within 24 h), and cultures. Cultured isolates underwent EUCAST E.Def 9.3.1 susceptibility testing.
Antifungal therapy (AFT) (mono/combination) combined with topical AFT (when possible) was
given according to the minimal inhibitory concentration (MIC), severity of the infection, and for
azoles, specifically, it was guided by therapeutic drug monitoring. The outcome was evaluated by
case record review. All patients underwent surgery guided by diagnostic biopsies from tissue and
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resection margins (195 samples in total). Comparing 2012–2015 and 2016–2019, the median number of
patients of surgical debridements was 3 and 2.5 and of diagnostic samples: microscopy/culture/PCR
was 3/3/6 and 10.5/10/10.5, respectively. The sensitivity of microscopy (76%) and Mucorales-PCR
(70%) were similar and microscopy was superior to that of culture (53%; p = 0.039). Initial systemic
AFT was liposomal amphotericin B (n = 12) or posaconazole (n = 1) given as monotherapy (n = 4)
or in combination with isavuconazole/posaconazole (n = 3/6) and terbinafine (n = 3). Nine patients
received topical amphotericin B. All received isavuconazole or posaconazole consolidation therapy
(n = 13). Mucormycosis related six month mortality was 3/5 in 2012–2015 and 0/7 patients in 2016–2019
(one patient was lost for follow-up). Implementation of combination therapy (systemic+topical
AFT/combination systemic AFT) and aggressive surgical debridement guided by optimised diagnostic
tests may improve the outcome of mucormycosis in haematologic patients.
Keywords: Mucorales; mucormycosis; haematology; neutropenia and mortality
1. Introduction
Mucormycosis is a rare, angio-invasive fungal infection [1]. The incidence is difficult to estimate
since systematic surveillance is not performed and cases may be classified as an unspecified invasive
fungal infection in the absence of definitive microbiological identification. The overall mortality is
almost 100% if untreated [2]. The most common genera involved are Rhizopus, Mucor, Rhizomucor,
and Lichtheimia [3].
In industrial countries, the major predisposing factor for mucormycosis is haematological
malignancy [1,4–6]. The most common manifestations are rhino-orbital-cerebral-mucormycosis
(ROCM) and pulmonary mucormycosis [1,5,7]. Pulmonary mucormycosis is the most frequent
manifestation in haematological patients [7–11]. Predisposing risk factors are prolonged and severe
neutropenia, high-dose corticosteroids, and iron overload (IOL) [12].
Factors that impact survival are the underlying condition, surgical and antifungal treatment,
and site of infection [1,2,7,10]. Two comprehensive reviews on mucormycosis reported an overall
mortality of 54% and 46%, respectively [2,13]. However, only 15.8% and 32% of the included
patients had haematological disease [2,13]. Disseminated infection is associated with haematological
disease [10,13] and carries the highest mortality (55–80%) [2]. Mortality is particularly high in relation
to allogeneic haematopoietic stem cell transplantation (allo-HSCT), in which 100 days mortality is
71% [14]. Early surgery and targeted antifungal treatment is crucial. A delay of six days or more to
the initiation of therapy has been shown to increase mortality in haematological patients receiving
amphotericin B [15].
The recent global guideline recommends CT scanning, microscopy with fluorescent brightener,
and culture for the diagnosis. Although typical microscopic findings are irregular broad pauci-septate
90◦ branching hyphae, artefacts may confuse the interpretations, particularly for technicians without
specific mycology expertise. Therefore, confirmation of microscopy is advised through in situ
immunohistochemistry or PCR, where these tests are available and with the caveat that no commercial
standardised PCR assays are available and the diagnostic performance of in house tests may vary [16].
Of note, no comments are offered regarding the use of these tests for guiding the need for repeated
surgery and fluorescent brightener is not universally implemented in clinical microbiology laboratories.
There are no validated antifungal breakpoints for Mucorales [3,17]. Amphotericin B is in vitro
active against most Mucorales species, but with high MICs against Cunninghamella species [3].
Isavuconazole and posaconazole have also shown in vivo and in vitro activity with MICs similar to
those found for Aspergillus, except against Mucor circinelloides [18]. Itraconazole has some activity,
but is not considered a first line therapy [19]. In contrast, fluconazole and voriconazole have no clinical
activity against Mucorales [3].
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Current guidelines from ECIL-6, ESCMID, and ECMM (European Confederation on Infection
in Leukaemia, European Society of Clinical Microbiology and Infectious Disease, and European
Confederation of Medical Mycology) recommend surgical debridement and high dose liposomal
amphotericin B (5 mg/kg) together with control of the underlying predisposing condition [16,17,20].
If the CNS is involved, a dosage of liposomal amphotericin B of 10 mg/kg initially is recommended [16,20].
First line treatment with high dose liposomal amphotericin B is strongly recommended, while
isavuconazole and posaconazole are recommended with moderate strength. Both triazoles are strongly
recommended as salvage treatments [16] and isavuconazole has been approved in the USA as an
alternative to liposomal amphotericin B as a first line treatment in mucormycosis. Its licence in Europe
is reserved for mucormycosis in patients for whom amphotericin B is inappropriate. Hyperbaric
oxygen can be considered as a supportive treatment, whereas deferasirox use in combination with
amphotericin B has been associated with increased mortality and should be avoided [16,17,20,21].
The outcome of mucormycosis remains poor despite advances in the antifungal armamentarium.
We sought to improve the outcome through an intensified multidisciplinary management approach
gradually introduced during 2016–2017 and consisting of surgical revision guided by rapid diagnostics
and aggressive combination antifungal therapy. We investigated the survival rate before and after the
intervention in a series of 13 patients with proven mucormycosis in 2012 to June 2019 and found no
mucormycosis related deaths since 2015.
2. Materials and Methods
This is a case-series based review including all patients with proven mucormycoses from January
2012 to June 2019 for whom mycology advice or diagnostic investigations were requested at the
national reference centre for mycology at Statens Serum Institut (SSI). The reference laboratory serves
the entire country with diagnostic tests and therapeutic advice as well as species identification and
reference susceptibility testing of referred isolates. The current study therefore probably includes
the vast majority of proven mucormycosis cases during the study period in Denmark, although we
cannot exclude that undiagnosed cases or non-proven cases in patients beyond therapeutic reach and
for whom diagnostics or consultation were deemed unnecessary were missed in the current period.
One case involved a patient from Sweden (#12) for whom the SSI was consulted concerning diagnostics
and management. One patient’s case has been published previously [22].
2.1. Laboratory Investigations
Biopsies were examined by Blankophor microscopy (SSI Diagnostica, Hillerød, Denmark), cultured
at YGC medium (Oxoid A/S Thermo Scientific, Roskilde, Denmark) and since 2017, investigated by
an in-house Mucorales specific PCR (see below). For one laboratory in Sweden, Sabouraud Dextrose
Agar (LabM, Lancashire, UK) supplemented with yeast extract 2.5 g/L (Oxoid, Roskilde, Denmark)
and chloramphenicol 50 µg/L was used. Species identification of cultured isolates was performed by
micro- and macro-morphology, supplemented by carbon assimilation using ATB ID32C (bioMérieux,
Marcy l’Etoile, France) [23], sequencing of the internal transcribed spacer (ITS) [24], and/or 18 S
analysis as necessary [25]. The EUCAST E.Def 9.3.1 reference method was used for susceptibility
testing [26]. For culture negative samples, the species identification was obtained by direct ITS PCR
and sequencing [24], 18 S analysis [25], and/or Mucorales specific PCR (described below). Thus, in all
cases, the involved species identification was molecularly confirmed.
2.2. Mucorales Diagnostic PCRs
(TaqMan) were introduced in 2017 and adopted with slight modifications from those described by
Salehi et al. [27]. One test detects Rhizopus microsporus, Rhizopus arrhizus, and Mucor spp. A second test
detects Lichtheimia spp. and Rhizomucor spp. DNA extraction Qiacube (Qiagen, Copenhagen, Denmark)
standard protocol is for blood and tissue samples, with up to 200 µL input volume and elution in
100 µL. Formalin fixed paraffin-embedded tissue samples were processed using Neo-clear (Sigma-
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Aldrich, Søborg, Denmark) followed by the protocol as described above. BALs were bead beaten and
DNA extracted on the NucliSENS easyMAG (Biomérieux, Ballerup, Denmark) platform with up to
1 mL input volume and elution in 60 µL. PCR analyses were performed on the Applied Biosystems 7500
and since mid-2018, the Quantstudio 5 thermocyclers (Roskilde, Thermo Fisher Scientific, Denmark).
Positive and negative template controls were applied, but not PCR inhibition or DNA extraction
controls. TaqMan Multiplex Master Mix (polymerase, buffer and dNTPs) as well as primers and probes
were acquired from Thermo Fisher Scientific (Glasgow, UK) except for a one locked nucleic acid probe
(R. microsporus) from IDT (Integrated DNA Technologies, München-Flughafen, Germany).
2.3. Optimised Clinical Management Principles Were As Follows
Aggressive primary surgery with complete resection of tissue and bone necrosis if possible, guided
by microscopy. Supporting imaging was performed in relevant cases. Consecutive debridements
were repeated often several times a week until the resection margins were clean. This was defined by
negative Blankophor microscopy, Mucorales specific PCR, and cultures of biopsies. Early diagnosis
was possible by means of same day Blankophor microscopy and same/next day Mucorales-PCR results.
Targeted antifungal therapy combined with topical therapy (when possible) was given according to
the MIC (mg/L) and severity of the infection. High trough azole levels above MIC were ensured by
target drug monitoring (TDM) [28]. Reconstruction with free flaps should be considered early in cases
of exposed bone to ensure optimal effect of the systemic antifungal treatment.
Fungal free survival and further clinical data were evaluated by case record review and history
provided by the treating physicians at the time of the ongoing fungal infection. Permission for data
review was given according to Danish quality-based research regulations.
2.4. Data Management
Positive rates for the diagnostic tests performed within the first 7 days were compared pairwise
using Fisher’s exact test (two-sided) with p value < 0.05 regarded significant using GraphPad Prism
8.3.0 (Prism – GraphPad, San Diego, CA, USA).
Overall, three, six, and 12 month survival rates were determined and three and six month
mucormycosis related deaths specifically were determined in the two periods 2012–2015 and 2016–2018.
3. Results
Thirteen cases of proven mucormycosis in patients with haematological disease (January 2012 to
June 2019) were identified and reviewed (Table 1). The median age was 36 years (range: 3–70 years).
The majority were males (8/13). Underlying diseases were aplastic anaemia (n = 4), acute myeloid
leukaemia (AML) (n = 3), acute lymphoblastic leukaemia (ALL) (n = 2), acute lymphoblastic T-cell
lymphoma (n = 1), Burkitt lymphoma (n = 1), diffuse large B-cell lymphoma (n = 1), and myelodysplastic
syndrome (MDS) (n = 1). A detailed case review is available in the Supplementary Materials.
The involved species were R. microsporus (n = 6), R. arrhizus (n = 2), Rhizomucor pusillus (n = 2),
Lichtheimia corymbifera (n = 1), Lichtheimia ramosa (n = 1), and Circinella muscae (n = 1). The localizations
of the infection were the sinuses (n = 7), brain (n = 3), lung (n = 3), liver (n = 1), skin (n = 1),
vertebrae (n = 1), and a sub-diaphragmatic abscess (n = 1). Three patients had infections involving
neighbour or non-contiguous sites of infection, including one patient with infection involving three
separate sites. Two patients with sinus involvement had CNS involvement. Three of the patients with
sinus involvement reported marijuana smoking. Five patients had received posaconazole as mould
prophylaxis for more than one week prior to the infection (excluding one patient with only three days
of posaconazole before the symptoms debut).
The results of diagnostic tests, species identification, and susceptibility data are summarised in
Tables 2 and 3. Overall, the fungal infections were confirmed by a positive microscopy in 12/13 patients,
by culture in 9/13 patients, and by molecular diagnostic tests in 8/10 patients. The median total number of
samples per patient sent for culture was 3 (range 1–18) in 2012–2015 and 10.5 (range 1–55) in 2016–2019.
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Similarly, the figures for microscopy were 3 (range 0–15) and 10.5 (range 2–60) in 2012–2015 and 2016–2019,
respectively. Finally, the number of molecular tests performed was 6 (range 0–24) and 10 (range 0–67)
per patient in 2012–2015 and 2016–2019, respectively (Table 2). Assuming that samples taken early are
more representative for the diagnostic performance than later during antifungal therapy, which included
control samples taken from presumed healthy tissue margins, we compared the positive rates including
only samples taken within the first 7 days (Table 3). The positive rate was similar for microscopy 76%
(29/38 samples) (95% CI: 61–87%), 18 S PCR 77% (10/13 samples) (95% CI: 50–92%), and Mucorales-PCR
70% (14/20) (95% CI: 48–86%) and higher than that for culture 53% (23/43) (95% CI: 39–67%) for culture
and ITS PCR 53% (10/19) (95% CI: 32–73%). The difference was statistically significant for microscopy
compared to culture (p = 0.039). When comparing samples taken from the same date, which underwent
microscopy and culture simultaneously at both the local and reference laboratories, none were positive
(0/37) at direct microscopy at the local laboratory (not using Blankophor staining), while 54% (21/39) were
positive with pauci-septate hyphae at the reference laboratory using Blankophor staining. The culture
positive rate was similar to 10% (5/49) at the local laboratory and 12% (5/42) at the reference laboratory.
All patients except one since 2016 underwent multiple surgical interventions up to 47 interventions
(extending from inspection to larger resections in one patient). After the introduction of Mucorales-PCR,
four out of five patients had species identification confirmed by Mucorales-PCR and three patients had
continuously Mucorales-PCR performed together with microscopy in relation to the surgical resections.
Over the years, patients have been diagnosed and treated in an increasingly closer collaboration between
treating physicians and the mycology unit, resulting in an increasing number of diagnostic tests and an
earlier diagnosis with species identification possible within 24 h due to the Mucorales-PCR (Table 2).
Initial systemic targeted treatment was liposomal amphotericin B in 12 out of 13 patients of whom
nine received this in combination with either posaconazole or isavuconazole (Table 4). Three patients
received dosages of >5 mg/kg liposomal amphotericin B initially due to suspicion of CNS involvement.
Three patients also received terbinafine and all received an azole as consolidation therapy. Nine out of
13 patients received topical amphotericin B, of whom two patients received amphotericin B intrathecally.
The number of patients receiving topical antifungal treatment was 3/5 in 2012–2015 and 6/8 in 2016–2019.
For intrathecal use, one patient was treated with amphotericin B deoxycholate 0.5 mg/dose daily or
three times a week intrathecally (#2). A second patient initially received liposomal amphotericin B 10
mg/dose, which was complicated by severe painful arachnoiditis (#13) and thereafter, amphotericin
B deoxycholate 0.1–0.2 mg/dose administrated during 20 min every other day and postoperatively,
amphotericin B 2.5 mg twice intrathecally [29].
Choice and dose of systemic antifungal treatment was adjusted according to species, susceptibility
pattern, anatomic localisation (local disease vs. disseminated and CNS involvement), and the TDM
result when measured. TDM was performed in 10 patients of whom seven received posaconazole
and four isavuconazole (patient #8 received posaconazole and isavuconazole sequentially). TDM was
individualized according to the fungal MICs, keeping a level clearly above the MIC, and according to
the severity and clinical course.
The overall three, six, and 12 month survival rates were 83% (10/12), 67% (8/12), and 58% (7/12),
respectively (Table 5), excluding one patient who was lost for follow-up one week after diagnosis.
The three and six months’ mucormycosis related mortality rates were 17% (2/12) and 25% (3/12),
respectively. The overall six month survival rates were 1/3 and 7/9 among patients with and without
CNS involvement. The six month survival rate was 6/9 for patients receiving combined systemic
antifungal treatment and 2/3 for those who received monotherapy. For patients receiving topical
antifungal treatment, 7/8 were alive after six months, as opposed to 1/4 for those who did not receive
topical antifungal treatment. Finally, six month mucormycosis related deaths occurred in 3/5 and 0/7
patients in 2012–2015 and 2016-June 2019, respectively. In seven out of 13 patients, the haematological
treatment was suspended during mucormycosis treatment, which affected the process of treatment of
underlying disease in 6 out of 13 patients. This led to haematological relapse in two further patients
after three and six months who were cured for mucormycosis (Table 5).
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Table 1. Baseline clinical characteristics of the 13 patients at the time of diagnosis of the Mucorales infection.
Case # Year Age(Years) Disease
a Immunosuppressive Regimen b
Prior Antifungal Prophylaxis
(Duration Indicated for Mould
Active Agents)
Regions Involved Species
# 1 2012 26 Aplastic anaemia Not received None Cerebrum Rhizomucor pusillus
# 2* 2013 3 Pre-B-ALL NOPHO ALL-protocol FLC Nose, sinus, orbita, andcerebrum
Lichtheimia
corymbifera
# 3 2015 42 AML
AML-17 protocol, sorafenib followed
by allogeneic HSCT. Sorafenib was
initiated during fungal infection due
to increasing MRD.
FLC Lung Rhizopusmicrosporus
# 4 2015 67 Pre-B-ALL MD Anderson regime PSC for three days Sinus and orbita Rhizopusmicrosporus
# 5 2015 28 Aplastic anaemia ATG, ciclosporine, prednisone, andtacrolimus
PSC for approximately four
months
Sinus, orbita, and
cerebrum
Rhizopus
microsporus
# 6 2016 36 Aplastic anaemia
ATG, cyclosporine, prednisone, and
mycophenolate followed by two
allogeneic HSCT
FLC Sinus and near orbita Circinella muscae
# 7 2016 57 AML FLAG-Ida PSC for three months Lung Rhizopusmicrosporus
# 8 2016 26 Burkitt lymphoma R-CODOX-M FLC Liver Lichtheimia ramosa
# 9 2017 48 Aplastic anaemia ATG, ciclosporine, and eltrombopag PSC for one month Sinus and orbital wall Rhizopusmicrosporus
# 10 2018 19 Acute T-celllymphoblastic lymphoma
NOPHO ALL-protocol and
chemotherapy intrathecally None
The hard palate, sinus,
and surrounding tissues Rhizopus arrhizus
# 11 2018 60 (Lost tofollow-up) AML FLAG-Ida PSC for approximately 1–2 weeks Sinus Rhizopus arrhizus
# 12 2018 70 MDS RAEB-2 Azacytidine FLC and then PSC ** for threemonths Forehead
Rhizopus
microsporus
# 13 2018 21
Diffuse large B-cell
lymphoma with CNS
involvement
CHOP × 3, R-CHOEP × 3, and
high-dose MTX and intrathecally
chemotherapy
Not prescribed
Vertebrae, lung abscess,
and a subdiaphragmatic
abscess
Rhizomucor pusillus
a ALL: Acute lymphoblastic leukemia, AML: Acute myeloid leukemia, MDS: Myelodysplastic syndrome, RAEB-2: Refractory anemia with excessive blasts-2. b NOPHO: Nordic Society
for Paediatric Haematology and Oncology, HSCT: Hematopoietic stem cell transplantation, MRD: Minimal residual disease, R-CODOX-M: rituximab, cycloposphamide, vincristine,
doxorubicin, vincristine and methotrexate, FLAG-Ida: Fludarabine, cytarabine and granulocyte colony-stimulating factor (G-CSF) and idarubicin, R-CHOEP: Rituximab, cyclophosphamide,
adriamycin, vincristine, etoposide, prednisone, MTX: Methotrexate, ATG: Antithymocyte globulin FLC: Fluconazole, PSC: Posaconazole * This case has previously been published in J
Pediatr Hematol Oncol 2017; 39: e211-15, ** The therapeutic drug monitoring levels were within the recommended ranges.
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Table 2. Overview of microbiological characteristics and diagnostic tests including all samples from each patient received at the SSI.
Case #
(Year)
Species Species Identification
(Final Confirmation)
Diagnostic Tests MIC (mg/L)
Blankophor Microscopy
(No. Total/ No. Positives)
Molecular Diagnostics
(No. Total/No. Positives)
Culture
No. Total/Isolates
(n with MICs *)
AMB PSC ISA TRB
ITS 18 S MUC-PCR
# 1 (2012) Rhizomucor pusillus ITS isolate for species ID 2/2 Not performed 3/3 (1) 0.75 0.125 Not done 0.5
# 2 (2013) ** Lichtheimia corymbifera ITS primary material 8/7 3/3 9/2 (2) 0.5–0.75 0.25 2 0.25
# 3 (2015) Rhizopus microsporus ITS and 18 S primarymaterial 3/3 3/3 3/3 3/0
# 4 (2015) Rhizopus microsporus ITS isolate for species ID 15/2 12/0 12/0 18/4 (4) 0.125–0.25 0.125–1 1–4 0.125–0.5
# 5 (2015) Rhizopus microsporus ITS isolate for species ID Not performed Not performed 1/1 (1) 0.5 0.25 2 0.5
# 6 (2016) Circinellamuscae
ITS and 18 S isolate for
species ID 5/2 5/0 5/0 5/1 (1) 0.06 ≤0.03 0.25 0.125
# 7 (2016) Rhizopus microsporus *** ITS primary material 3/3 4/3 3/3 4/0
# 8 (2016) Lichtheimia ramosa 18 S primary material 2/2 2/0 2/2 1/0
# 9 (2017) Rhizopus microsporus Mucorales-PCR, ITS, and18 S primary material 18/9 12/1 19/4 21/2 19/4 (2) 0.5–1 0.125–0.125 0.5–1 0.25–0.5
# 10 (2018) Rhizopus arrhizus Mucorales-PCR and ITSprimary material 60/16 5/4 4/1 58/17 55/2 (2) 0.125 0.25 0.5–1 >4
# 11 (2018) Rhizopus arrhizus Mucorales-PCR and ITSprimary material 10/9 3/2 10/10 10/8 (6) 0.25 0.25–0.5 1–2 >4
# 12 (2018)
a Rhizopus microsporus ITS isolate for species ID 12/2 Not performed 50/3 (1) 0.25 0.5 2 Not done
# 13 (2018) Rhizomucor pusillus Mucorales-PCR and 18 Sprimary material 11/5 12/4 6/3 9/5 11/0
Cases combined for the early and late time period
# 1–5 (2012–2015) Median 3 (range 1–18) Median 6 (range 0–24) Median 3 (range1–18)
# 6–13 (2016–2019) Median 10.5 (range 2–60) Median 10 (range 0–67) Median 10.5(range 1–55)
The included samples and isolates are the ones received at SSI for mycologic diagnostics either directly from the clinical department or referred from the clinical microbiological department.
The MIC values are shown with ranges if more than one isolate. ITS: Internal transcribed spacer, MUC-PCR: Mucorales-PCR, AMB: Amphotericin B, ISA: Isavuconazole, PSC: Posaconazole,
TRB: Terbinafine, * Cases with positive cultures only. ** This case has previously been published in J Pediatr Hematol Oncol 2017; 39: e211–15. *** The first diagnostic ITS was performed on
pleurafluid at the local clinical microbiological department. a Patient diagnosed and managed in Sweden according to advice from the SSI.
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Table 3. Diagnostic tests performed within the first 7 days from proven diagnosis.
Case # (Year) Species
Diagnostic Tests
Blankophor Microscopy
(No. Total/No. Positives)
Molecular Diagnostics (No. Total/No. Positives) Culture * No.
Total/IsolatesITS 18 S MUC-PCR
# 1 (2012) Rhizomucor pusillus 2/2 Not performed 3/3
# 2 (2013) ** Lichtheimia corymbifera Not performed Not performed 1/1
# 3 (2015) Rhizopus microsporus 3/3 3/3 3/3 3/0
# 4 (2015) Rhizopus microsporus Not performed Not performed 1/1
# 5 (2015) Rhizopus microsporus Not performed Not performed 1/1
# 6 (2016) Circinella muscae 1/1 Nor performed 1/1
# 7 (2016) Rhizopus microsporus *** Not performed 1/1 1/0
# 8 (2016) Lichtheimia ramosa 1/1 1/1 Not performed
# 9 (2017) Rhizopus microsporus 7/6 5/1 6/4 7/1 7/3
# 10 (2018) Rhizopus arrhizus 4/3 4/3 1/1 1/1 4/2
# 11 (2018) Rhizopus arrhizus 10/9 3/2 10/10 10/8
# 12 (2018) Rhizopus microsporus 8/2 Not performed 9/3
# 13 (2018) Rhizomucor pusillus 2/2 3/0 2/1 2/2 2/0
In total, positive rates indicated in parenthesis 38/29 (76%) a 19/10(53%) 13/10 (77%) 20/14 (70%) 43/23 (53%)
a
* Culture includes isolates received from the local department for clinical microbiology. ** This case has previously been published in J Pediatr Hematol Oncol 2017; 39: e211-15. *** The
first diagnostic ITS was performed directly on pleurafluid at the local clinical microbiological department. The first culture is pleura fluid. a p = 0.0389 comparing microscopy and culture.
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Table 4. Systemic, topical, surgical, and supportive therapy and mucormycosis outcome of 13 haematological patients.
Case # Systemic Antifungal Treatment,Daily Dosage
Azole Serum Concentration
During Therapy *** Median
(Range) (n Measurements)
Topical Antifungal Treatment Surgery SupportiveTreatment
Outcome of
Mucormycosis at the
End of Follow Up
# 1 2012
Combination L-AMB 300 mg * × 1
and PSC 300 mg × 3 until death for
approximately 2–3 weeks
s-posaconazole 1.05
(1) Not applied
One drainage and two
craniotomias Not received
Died within one
month
# 2 ** 2013
Combination L-AMB 5–9 mg/kg,
PSC 37.5–75 mg/kg, and TRB 4
mg/kg for 5, 33, and 2 months, rp.
s-posaconazole
1.55 (0.42–4.73)
(110)
AMB deoxycholate in the sinuses
and intrathecally through
Ommaya reservoir
14 resections including sinus
surgeries, removal of eye, brain
tissue, and hard palate
Hyperbaric oxygen 33
sessions Cured
# 3 2015
Monotherapy L-AMB (3–5 mg/kg)
according to kidney function and
adjusted to 3 mg/kg until resection
for 10 months followed by
monotherapy PSC 300 mg × 1
maintenance
s-posaconazole
0.5 (0.28–1.5)
(5)
Topical AMB deoxycholate in the
lung cavity
One unilateral
pleurapneumectomy G-CSF Cured
# 4 2015
Combination L-AMB 5 mg/kg and
PSC 300 mg until death for 4 months
with a few treatment interruptions
s-posaconazole
1.5 (0.0–4.2)
(24)
AMB deoxycholate in the sinuses Five resections Not received
Died of fungal
infection after four
months
# 5 2015
Combination L-AMB 3.5 mg/kg for 1
month and PSC 300 mg for 2 weeks
until death
Not done Not applied One surgical biopsy/uncinectomyand two follow-up debridements
Iron chelation in
relation to iron
overload
Died of fungal
infection after one
month
# 6 2016
Combination L-AMB 5 mg/kg daily
or 10 mg/kg three times a week for
10 months. PSC 300–450 mg until
death after 15 months
s-posaconazole
0.75 (0–2.4)
(28)
AMB deoxycholate in the sinuses
as well as inhalation Four excisions/resections Not received Presumably cured
# 7 2016
Monotherapy L-AMB 5 mg/kg for 3
weeks and then combination of ISA
200 mg and TRB 250 mg for 4 months
Not done Not applied One lobectomy G-CSF Presumably cured
# 8 2016
Monotherapy PSC 300 mg for 1
month and hereafter, monotherapy
ISA 200–300 mg according to TDM
for 8 months
s-posaconazole
1.2 (1.1–1.6)
(7)
s-isavuconazole
4.8 (2.4–8.4)
(22)
Not applied Liver drainage and one resectionwith no hyphae G-CSF Cured
# 9 2017
L-AMB 2–5 mg/kg for four months
and ISA 200 mg for 16 months.
Combination was given for 3 months
s-isavuconazole
3.8 (1.4–5.7)
(6)
L-AMB installations in the
sinuses and intraorbitally. AMB
deoxycholate inhalation.
Switched to amphotericin B
deoxycholate intranasally
15 resections
Excluding two biopsies prior to
the resections, which were
inconclusive
G-CSF
Granulocyte
transfusions and
hyperbaric oxygen
approximately 11
sessions
Cured
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Table 4. Cont.
Case # Systemic Antifungal Treatment,Daily Dosage
Azole Serum Concentration
During Therapy *** Median
(Range) (n Measurements)
Topical Antifungal Treatment Surgery SupportiveTreatment
Outcome of
Mucormycosis at the
End of Follow Up
# 10 2018
Combination L-AMB and ISA. AMB
dosage 5–8 mg/kg initially and then
reduced when fungal infection was
controlled. ISA 200–600 mg for 10
months adjusted after TDM until
death. Combination was given in 5
months.
s-isavuconazole
6.2 (1.2–15.4)
(66)
AMB deoxycholate in the sinuses
47 interventions extending from
inspection and sampling to
approximately 18 surgical
revisions including four larger
resections
Hyperbaric oxygen 30
sessions
and G-CSF
Cured
# 11 2018
Monotherapy L-AMB 5 mg/kg for 3
weeks and monotherapy ISA 200 mg.
Duration of ISA is unknown.
Not done AMB deoxycholate in the sinuses Two resections G-CSF
Presumably Cured
(no longterm
follow-up)
# 12 2018 Combination L-AMB 5 mg/kg for 3weeks and PSC 300 mg for 3 months
s-posaconazole
1.3 (0.85–2.1)
(14)
L-AMB in the wound One resection and one skin graft
Iron chelation in
relation to iron
overload
Cured
# 13 2018
Combination L-AMB and ISA for 7
months. L-AMB dosage initially
7–10 mg/kg and then 3 mg/kg. ISA
300 mg and TRB 1–2 g/day are still
ongoing.
s-isavuconazole range
3.3 (1.5–7.3)
obtained August-2019
(26)
L-AMB intrathecally initially.
Then changed to AMB
deoxycholate
Two vertebrae resections and one
lobectomy Not received
Cured mucormycosis
treatment is still
ongoing
s: serum concentration measured in mg/L. L-AMB: Liposomal amphotericin B, AMB: Amphotericin B, TRB: Terbinafine, G-CSF: Granulocyte colony-stimulating factor. * Information
regarding weight was not accessible. ** This case has previously been published in J Pediatr Hematol Oncol 2017; 39: e211–15. *** Therapeutic drug monitoring. The reported azole
concentrations shown are the ones measured at Statens Serum Institute.
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Table 5. Haematological status and survival.
Case # Haematological Disease Status of Haematological Disease atFungal Infection Diagnosis and Treatment
Chemotherapy/
Immunosuppression Suspended
Consequences for
Haematological Course
Survival 3
Months
Survival 6
Months
Survival
12 Months
# 1 2012 Aplastic anaemia NA No Yes. Unable to plan allogeneicHSCT No No No
# 2 * 2013 ALL Remission after induction Yes No Yes Yes Yes
# 3 2015 AML Increasing MRD Yes Yes. Allogeneic HSCT postponed Yes Yes Yes
# 4 2015 ALL
Remission after first hyper-CVAD with
rituximab and intrathecal MTX and
cytarabine
Yes Yes. Unable to proceed withchemotherapy Yes No No
# 5 2015 Aplastic anaemia Fungal infection developed during secondtry with ATG Yes
Yes. Unable to proceed with
immunosuppressive agents No No No
# 6 2016 Aplastic anaemia Fungal infection developed during secondtry with ATG Yes No Yes Yes Yes
# 7 2016 AML Complete remission after FLAG-ida Yes Yes. Prohibitive for allogeneicHSCT resulting in relapse Yes No No
# 8 2016 Burkitt lymphoma Neutropenic during the last course ofchemotherapy No No Yes Yes Yes
# 9 2017 Aplastic anaemia Fungal infection developed after initiation ofATG No No Yes Yes Yes
# 10 2018 Acute T-celllymphoblastic lymphoma
Fungal infection developed during induction
and intrathecal MTX and cytarabine Yes Yes. Later on relapse Yes Yes No
# 11 2018 AML Complete remission after FLAG-Ida No No Unknown Unknown Unknown
# 12 2018 MDS MDS RAEB-2on azacythidine No No Yes Yes Yes
# 13 2018 Diffuse large B-celllymhoma Remission and finalized R-CHOEP No No Yes Yes Yes
* This case has previously been published in J Pediatr Hematol Oncol 2017; 39: e211–15. ALL: Acute lymphoblastic leukemia, AML: Acute myeloid leukemia, MDS: Myelodysplastic
syndrome, NA: Not available, MRD: Minimal residual disease, CVAD: cyclophosphamide, vincristine, doxorubicine, dexamethasone, MTX: Methotrexate, ATG: Antithymocyte globulin,
FLAG-Ida: Fludarabine, cytarabine and granulocyte colony-stimulating factor (G-CSF) and idarubicin, R-CHOEP: Rituximab, cyclophosphamide, Adriamycin, vincristine, etoposide and
prednisone, RAEB-2: Refractory anemia with excessive blasts-2. HSCT: Haematopoetic stem cell transplantation. NA: Not available.
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4. Discussion
We report 13 cases with proven Mucorales infection diagnosed during 2012–18 and with an overall
three, six, and 12 month survival rate of 83%, 67%, and 58%, respectively, with no mucormycosis
related deaths after 2015. A multidisciplinary aggressive management approach including a new in
house Mucorales-PCR test was introduced during 2016 and 2017, leading to a three times doubling
of diagnostic tests per patient for diagnosis and guidance of surgery. All patients diagnosed during
2016–2018 survived the infection and none of the patients with sinus mucormycosis progressed to
orbital or CNS involvement. All but one of the patients who received topical antifungal treatment
survived the infection, which suggests a potential survival benefit. Although numbers are low,
we speculate that the apparently improved outcome compared to patients diagnosed earlier may
be a result of a closer collaboration between specialties, leading to early diagnosis and diagnostics
driven surgical treatment. Microscopy and Mucorales-PCR enable a more precise guidance of surgery,
leading to a more favourable mucormycosis outcome in close collaboration between the haematologist,
infectious disease physician, and surgeon, with focus on topical treatment in relation to surgery.
Combined surgery and antifungal treatment have previously been associated with a better outcome
of mucormycosis in several studies [2,19,30]. However, surgical debridement for mucormycosis is
often mutilating, especially in haematological patients with profound thrombocytopenia. These factors
necessitate a careful risk assessment, balancing the risks and cosmetic consequences associated with
the surgery with the certainty of the diagnosis, amount of affected tissue, and likely outcome. Manesh
et al. found a higher mortality in haematological patients and ascribed it to lower rates of surgical
debridements [31]. Vironneau et al. found that patients with ROCM not eligible for surgery were more
likely to die from their mucormycosis and that local control with repeated and wide surgery had an
impact on survival [32]. Rapid diagnostics allow early antifungal therapy and surgery and consequently
may limit the extent and number of subsequent surgical revisions, caused by the aggressive angio
invasive growth of Mucorales. Blankophor microscopy was more sensitive than standard microscopy
and culture and allowed a same day detection, but not a species identification. Positive rates were
comparable for 18 S, Mucorales-PCRs, and microscopy, but the advantage of the Mucorales-PCR
was a rapid detection, including species identification (within 24 h). This is informative regarding
optimal antifungal therapy due to the differential intrinsic susceptibility pattern across the Mucorales
species [18].
The fact that the treatment for the underlying haematological disease was suspended in around
half of the patients underlines the importance of early diagnosis and management of mucormycosis to
avoid both fungal infection related mortality and increased mortality due to delayed therapy of the
underlying disease.
Our study has limitations. A relatively low number of patients were included from an eight
year period during which new treatment modalities for the underlying diseases as well as for fungal
infections (introduction of isavuconazole) have occurred. Mucormycosis is, however, a rare infection
and thus, it is challenging to obtain larger case series with patients with similar underlying conditions
and with a uniform approach to diagnosis and management. Other prospective studies, not restricted to
haematological patients, have included 18 to 32 proven cases [21,33,34] and retrospective haematological
studies of 20 to 74 proven cases during up to 20 year study periods [8,9,35,36]. We only included patients
with proven mucormycosis, such as the study by Kara et al. [35]. This is both a strength (certainty of
diagnosis) and a limitation. The latter because excluding cases without a proven infection may confer
a risk of selection bias towards patients eligible for (invasive) sampling and subsequent therapy and
thus, with a better a priori chance for survival. This concern is supported by two observations. First, a
low median age among our patients was found compared to several other studies (36 years versus
40–54 years) [2,5,7,11,13,21,33,34,36]. However, patients in the only other study limited to proven cases
also had a low median age of 25 years, yet reported a higher one month overall mortality rate of 55%
(11/20), of which 20% (4/20) died from mucormycosis [35]. Second, a minority of our patients and
those in the prior study limited to proven cases [35] had pulmonary mucormycosis, which has been
J. Fungi 2020, 6, 268 13 of 16
associated with a higher mortality compared to sinus mucormycosis [5,7,13]. Pulmonary mucormycosis
has been reported as the most common Mucorales manifestation in haematological patients [7–11].
However, Mucorales are ubiquitous and may be found in airway samples as contaminants, leading to
an overestimation of the number of pulmonary infections when non-proven cases are included. On the
other hand, the challenges associated with invasive thoracic procedures in haematological patients
may lead to an underestimation of the true number of proven cases. Finally, the reported mortality is
affected by the fact that all cases with mucormycosis involving CNS occurred before 2016, which is
associated with a poorer outcome. However, the absence of CNS cases may also be a result of better
and earlier disease control.
In conclusion, our data suggest improved treatment outcomes for mucormycosis using the
following approach: An initial management including (1) early combination therapy with systemic
liposomal amphotericin B 5 mg/kg and isavuconazole (with or without terbinafine), (2) imaging
supported evaluation of extension and early diagnostic biopsies or immediate resection, most favourable
from a sterile site with consideration of risk of surgical complications, (3) real time Blankophor
microscopy of removed tissue and biopsies from resection margins (guiding subsequent surgical
revisions), and (4) topical amphotericin B treatment when possible in connection with diagnostic
resection, (5) dose adjustment of the antifungal treatment according to species, susceptibility pattern,
and anatomic localisation (local disease vs. disseminated and CNS involvement) and TDM result,
and (6) repeated surgical resections performed until radical resection is achieved. This requires a
multidisciplinary approach and close collaboration between the treating physician, the surgeon, and
the microbiologist providing real-time Blankophor microscopy and Mucorales-PCR guidance (within
24 h). We suggest that the optimised management principle involving early diagnosis with species
identification undoubtably had a clinical impact. However, further studies of the management of this
devastating infection are warranted.
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